Announcements Trials

Browse Landscape

Phase

Phase 2 24 Phase 3 6 Phase 1 5 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Neoplasm Metastasis 1

Interventions

Gemcitabine 9 Docetaxel 8 Androgen Antagonists 7 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 6 Magnetic Resonance Spectroscopy 6 gallium 68 PSMA-11 5 Prednisone 5 Leuprolide 5 Goserelin 5 Cisplatin 5 enzalutamide 4 bicalutamide 4 Triptorelin Pamoate 4 Radiosurgery 4 Carboplatin 4 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4 luprolide acetate gel depot 3 Flutamide 3 Celecoxib 3 valrubicin 2 pembrolizumab 2 nilutamide 2 cabazitaxel 2 abiraterone 2 Zoledronic Acid 2 Vinblastine 2 Specimen Handling 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Nivolumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × relugolix × Genitourinary × Clear all

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡